This US-based KOL discusses their prescribing habits for agitation in Alzheimer’s disease as well as their thoughts on the mechanisms behind agitation treatments. They also speak on the barriers that are impacting usage of anti-amyloids and share their opinions on other targets for Alzheimer’s disease.

This interview was conducted on 19 January 2024.

If you are a KOL Insight Subscriber, you may also access the interview from our KOL Insight portal .

Biomedtracker's KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900.

For our disclosures, please read the Biomedtracker Research Standards